VINCASAR PFS

Post-LOE

vincristine sulfate

Entera Bio

ANDAINJECTIONINJECTABLE

Approved

Jul 1987

Lifecycle

Post-LOE

Competitive Pressure

30/100

Clinical Trials

Data completeness

2/8 — Basic

Drug data last refreshed 1w ago

Mechanism of Action

Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.

Indications

Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.

Clinical Trials (2)

NCT03851081Phase 1/2Withdrawn

Inotuzumab Ozogamicin and Vincristine Sulfate Liposome in Treating Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia

Started Jan 2021

Allogeneic Hematopoietic Stem Cell Transplantation RecipientBlasts 5 Percent or More of Bone Marrow Nucleated CellsBlasts 5 Percent or More of Peripheral Blood White Cells+5 more

NCT02072785Phase 3Unknown

Phase III Study of Vincristine Sulfate Liposome For Injection In Adults With Naïve Acute Lymphoblastic Leukemia

Started Jun 2013

480 enrolled

Adult Acute Lymphoblastic Leukemia

Company

Worked on VINCASAR PFS at Entera Bio? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.